Lista de obras - Mark J McKeage - Dominio Público Uruguay

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent

artículo científico publicado en 2006

A clinical and pharamcological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue ⬇️

artículo científico publicado el 1 de enero de 1992

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma

artículo científico publicado en 2011

A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration

artículo científico publicado en 1995

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

artículo científico publicado en 2011

ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.

artículo científico publicado en 2010

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

artículo científico publicado en 2017

Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective

artículo científico publicado en 2006

Advances in Platinum Complex Cancer Chemotherapy

artículo científico publicado en 1992

Antitumor activity of gold(i), silver(i) and copper(i) complexes containing chiral tertiary phosphines

artículo científico publicado en 1998

Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.

artículo científico publicado en 2006

Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients

artículo científico publicado en 2004

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

artículo científico publicado en 2015

COMPARATIVE PROTEIN BINDING, STABILITY AND DEGRADATION OF SATRAPLATIN, JM118 AND CISPLATIN IN HUMAN PLASMAIN VITRO

artículo científico publicado en 2008

Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group ⬇️

artículo científico publicado el 1 de mayo de 1990

Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer

artículo científico publicado en 1994

Clinical Trials of Vascular Disrupting Agents in Advanced Non–Small-Cell Lung Cancer ⬇️

artículo científico publicado el 22 de abril de 2011

Comparative adverse effect profiles of platinum drugs.

artículo científico publicado en 1995

Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.

artículo científico publicado en 2010

Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons

scientific journal article

Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity

artículo científico publicado en 2017

Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.

artículo científico publicado en 2010

Determination of xanthenone-4-acetic acid in mouse plasma by high-performance liquid chromatography ⬇️

artículo científico publicado el 8 de marzo de 1991

Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue

scientific journal article

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

scientific article published on April 2010

EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand

artículo científico publicado en 2017

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

scientific article published on 07 March 2019

Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study ⬇️

artículo científico publicado en 2019

Emerging roles of metal solute carriers in cancer mechanisms and treatment.

artículo científico

Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo.

artículo científico publicado en 2013

Examination of the effects of oxidation and ring closure on the cytotoxicities of the platinum complexes of N-(2-hydroxyethyl)ethane-1,2-diamine and ethane-1,2-diamine-N,N'-diacetic acid

artículo científico publicado en 2002

Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC

scientific article published on 25 November 2019

Gold opens mitochondrial pathways to apoptosis

artículo científico publicado en 2002

Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid

artículo científico publicado en 1991

Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs.

artículo científico publicado en 2014

Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer

artículo científico publicado en 2019

In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.

artículo científico publicado en 2007

Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand

article

Increased targeting of adenine-rich sequences by (2-amino-2-methyl-3-butanone oxime)dichloroplatinum(II) and investigations into its low cytotoxicity

artículo científico publicado en 2000

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents

artículo científico publicado en 1993

Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat

scientific article published on 01 February 1994

Legionellosis due to Legionella pneumophila serogroup 6: report of three cases.

artículo científico publicado en 1984

Lobaplatin: a new antitumour platinum drug

artículo científico publicado en 2001

Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test

artículo científico publicado en 2017

Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

artículo científico publicado en 2002

Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial.

artículo científico publicado en 2012

Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.

artículo científico publicado en 1994

Membrane transporters as determinants of the pharmacology of platinum anticancer drugs.

artículo científico

Mini-Wright Peak Flow Meter

scientific article published on 01 December 1982

Mitozolomide-induced sensitisation of mammalian cells in vitro to radiation.

artículo científico publicado en 1989

Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles

artículo científico publicado en 2015

Muscle ultrasound in the assessment of oxaliplatin-induced neurotoxicity

artículo científico publicado en 2019

Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.

artículo científico publicado en 2009

Neuropathies associated with oxaliplatin therapy ⬇️

artículo científico publicado el 1 de junio de 2012

Neuroprotective interactions in rats between paclitaxel and cisplatin

scientific article published on 01 January 1999

New platinum agents. A comparison in ovarian cancer

artículo científico publicado en 1994

New-generation platinum drugs in the treatment of cisplatin-resistant cancers

artículo científico publicado en 2005

Nucleolar damage correlates with neurotoxicity induced by different platinum drugs

artículo científico publicado en 2001

Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel

artículo científico publicado en 2007

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer

artículo científico publicado en 1999

Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss

artículo científico publicado en 2005

Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons

artículo científico publicado en 2011

Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.

artículo científico publicado en 2009

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

artículo científico publicado en 2012

Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity.

scientific article published on June 2003

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

artículo científico publicado en 1997

Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.

artículo científico publicado en 2013

Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer

artículo científico publicado en 1997

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

artículo científico publicado en 2017

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

artículo científico publicado en 2009

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer ⬇️

artículo científico publicado el 1 de mayo de 1998

Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice

artículo científico publicado en 1991

Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991.

artículo científico publicado en 1991

Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches

artículo científico publicado en 1999

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug

artículo científico publicado en 1993

Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates

artículo científico publicado en 1994

Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation

artículo científico publicado en 2017

Preparation, Characterization, DNA Binding, andin VitroCytotoxicity of the Enantiomers of the Platinum(II) ComplexesN-Methyl-,N-Ethyl- andN,N-Dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II)

artículo científico publicado en 1997

Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer

artículo científico publicado en 1997

Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics.

artículo científico publicado en 2016

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

artículo científico publicado en 2008

Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer

artículo científico publicado en 2011

Rapid biotransformation of satraplatin by human red blood cells in vitro

artículo científico publicado en 2002

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

artículo científico publicado en 2000

Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain ⬇️

artículo científico publicado en 2019

Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes

artículo científico publicado en 2000

Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity.

artículo científico publicado en 2015

Saliva lithium: a poor predictor of plasma and erythrocyte levels

artículo científico publicado en 1989

Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro

artículo científico publicado en 2005

Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation

artículo científico publicado en 2007

Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo

artículo científico publicado en 1994

Screening for Anaplastic Lymphoma Kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in New Zealand

artículo científico publicado en 2019

Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent

artículo científico publicado en 2014

Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry

artículo científico publicado en 2006

Stereoselective PT complexes as probes of the mechanism of action of Pt anti-cancer drugs ⬇️

artículo científico publicado en 1995

Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin ⬇️

artículo científico publicado el 1 de enero de 1997

Streptococcus zooepidemicus cellulitis and bacteraemia in a renal transplant recipient

artículo científico publicado en 1990

Structural and solution chemistry of gold(I) and silver(I) complexes of bidentate pyridyl phosphines: selective antitumour agents

scholarly article

Tamoxifen and chemotherapy for refractory metastatic malignant melanoma

artículo científico publicado en 1993

The Effects of Synthetically Modified Natural Compounds on ABC Transporters

artículo científico publicado en 2018

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer

artículo científico publicado en 2008

Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

artículo científico publicado en 2009

Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells

scientific article published on 08 September 2019

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review

artículo científico publicado en 2020

Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin

scientific article published on 01 January 1999

cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro.

artículo científico publicado en 2001

Lista de obras de Mark J McKeage

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent

A clinical and pharamcological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue ⬇️

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma

A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective

Advances in Platinum Complex Cancer Chemotherapy

Antitumor activity of gold(i), silver(i) and copper(i) complexes containing chiral tertiary phosphines

Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.

Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

COMPARATIVE PROTEIN BINDING, STABILITY AND DEGRADATION OF SATRAPLATIN, JM118 AND CISPLATIN IN HUMAN PLASMAIN VITRO

Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group ⬇️

Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer

Clinical Trials of Vascular Disrupting Agents in Advanced Non–Small-Cell Lung Cancer ⬇️

Comparative adverse effect profiles of platinum drugs.

Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.

Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons

Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity

Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.

Determination of xanthenone-4-acetic acid in mouse plasma by high-performance liquid chromatography ⬇️

Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study ⬇️

Emerging roles of metal solute carriers in cancer mechanisms and treatment.

Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo.

Examination of the effects of oxidation and ring closure on the cytotoxicities of the platinum complexes of N-(2-hydroxyethyl)ethane-1,2-diamine and ethane-1,2-diamine-N,N'-diacetic acid

Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC

Gold opens mitochondrial pathways to apoptosis

Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid

Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs.

Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer

In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.

Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand

Increased targeting of adenine-rich sequences by (2-amino-2-methyl-3-butanone oxime)dichloroplatinum(II) and investigations into its low cytotoxicity

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents

Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat

Legionellosis due to Legionella pneumophila serogroup 6: report of three cases.

Lobaplatin: a new antitumour platinum drug

Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test

Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial.

Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.

Membrane transporters as determinants of the pharmacology of platinum anticancer drugs.

Mini-Wright Peak Flow Meter

Mitozolomide-induced sensitisation of mammalian cells in vitro to radiation.

Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles

Muscle ultrasound in the assessment of oxaliplatin-induced neurotoxicity

Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.

Neuropathies associated with oxaliplatin therapy ⬇️

Neuroprotective interactions in rats between paclitaxel and cisplatin

New platinum agents. A comparison in ovarian cancer

New-generation platinum drugs in the treatment of cisplatin-resistant cancers

Nucleolar damage correlates with neurotoxicity induced by different platinum drugs

Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer

Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss

Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons

Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity.

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.

Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer ⬇️

Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice

Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991.

Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug

Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates

Predicting effects on oxaliplatin clearance: in vitro, kinetic and clinical studies of calcium- and magnesium-mediated oxaliplatin degradation

Preparation, Characterization, DNA Binding, andin VitroCytotoxicity of the Enantiomers of the Platinum(II) ComplexesN-Methyl-,N-Ethyl- andN,N-Dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II)

Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer